No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Diagnostics & Research
Metropolis Healthcare Limited functions as a prominent diagnostic service provider throughout India. The company delivers a comprehensive array of clinical laboratory testing, specialized diagnostic profiles, and associated support services. Its capabilities span diverse medical fields, encompassing oncology, neurology, gynecology, and nephrology. Furthermore, Metropolis offers a variety of health check-up packages specifically tailored for different demographic groups, including men, women, senior citizens, youth, and corporate clients. These tests are vital for disease prediction, early identification, diagnostic screening, confirmation, and continuous monitoring. Beyond its core diagnostic offerings, the company also extends its expertise to corporate wellness programs, hospital laboratory management solutions, and clinical research. As of March 31, 2022, Metropolis had established an extensive network comprising 171 clinical laboratories, 9,000 sample collection points, and 704 assisted referral centers. Founded in 1980, the company's corporate headquarters are situated in Mumbai, India.
www.metropolisindia.comNo one on the platform currently holds METROPOLIS.NS.
No tracked institution reports a position in METROPOLIS.NS as of their last filing.
No one on the platform has traded METROPOLIS.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 11.6% | 27.0% | 42.8% | — | — | — |
| Rev. Growth % | 23.6% | 10.5% | ||||
| Profit Margin % | 11.5% | 12.6% | 14.7% | |||
| Free Cash Flow Margin % | 18.2% | 17.3% | 16.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $19.0B | +15.3% | $12.37 | $12.00–$13.20 | — | 18 |
| 2028 | $21.8B | +14.8% | $15.59 | $14.63–$17.63 | — | 18 |
| 2029 | $24.7B | +13.2% | $19.29 | $18.32–$21.96 | — | 13 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $2.70 | $2.72 | +0.7% |
| 2026-05-13 | $2.57 | $2.50 | -2.7% |
| 2026-02-04 | $2.23 | $2.31 | +3.6% |
| 2025-11-04 | $2.73 | $2.55 | -6.6% |
| 2025-08-07 | $2.00 | $2.17 | +8.5% |
| 2025-05-13 | $1.98 | $2.17 | +9.6% |
| 2025-02-04 | $1.79 | $1.53 | -14.5% |
| 2024-11-08 | $9.05 | $9.03 | -0.2% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| METROPOLIS.NSMetropolis Healthcare Limited | $572.50 | -2.22% | $118.7B | — |
| JLHL.BOJupiter Life Line Hospitals Limited | $275.40 | -1.27% | $91.9B | — |
| JLHL.NSJupiter Life Line Hospitals Limited | $275.55 | -1.29% | $90.3B | — |
| MEDPLUS.BOMedPlus Health Services Limited | $655.25 | -0.81% | $78.7B | — |
| MEDPLUS.NSMedPlus Health Services Limited |
| $656.30 |
| -0.58% |
| $78.8B |
| — |
| PGHL.NSProcter & Gamble Health Limited | $5408.00 | -0.06% | $89.8B | — |
| SHAILY.NSShaily Engineering Plastics Limited | $3181.80 | -2.98% | $146.3B | — |
Source: Financial Modeling Prep · peers by sector/industry